Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ZEUS trial testing ziltivekimab, an anti-inflammatory drug that targets interleukin-6, failed to deliver the cardiovascular benefit researchers hoped for, STAT News reported from the American Heart Association's 2026 conference. The result is a setback for Novo and for the thesis that calming inflammation can prevent heart attacks and strokes.

Despite the miss, cardiologists interviewed by STAT said the negative data does not sink the broader field. "These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease," one researcher told the publication. The view is that the drug or the trial design, not the underlying biology, came up short.

Inflammation has drawn heavy pharmaceutical investment as a target beyond cholesterol. Expect continued work on anti-inflammatory approaches even as individual candidates stumble. For Novo, already navigating competitive pressure in its core GLP-1 franchise, the failure removes one pipeline bet in cardiovascular disease.